ReviewCureus2025
Evolving Surgical Approaches in the Management of Pancreatic Masses: From Open Resection to Minimally Invasive and Robotic Techniques.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reducing Complications in Pancreaticoduodenectomy.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic masses represent a heterogeneous spectrum of neoplasms, ranging from benign lesions such as serous cystadenomas to malignant tumors such as pancreatic ductal adenocarcinoma (PDAC). Timely and accurate differentiation among these entities is essential for devising effective therapeutic strategies. Recent advancements in diagnostic modalities, surgical techniques, and perioperative care have significantly influenced the management of pancreatic masses. This narrative review synthesizes current literature and clinical practices related to the surgical management of pancreatic masses. It examines the evolution of diagnostic tools, operative approaches, perioperative management, and the integration of emerging technologies in clinical decision-making. Imaging modalities such as contrast-enhanced CT, MRI, and endoscopic ultrasound have improved the precision of diagnosis and staging. Histopathological confirmation remains the gold standard for definitive diagnosis. Surgical options, including partial and total pancreatectomy, are tailored according to tumor type and stage, with resection being the only curative treatment for PDAC. Minimally invasive approaches, such as laparoscopic and robotic-assisted surgeries, offer the benefits of reduced morbidity and faster recovery while maintaining oncological outcomes. Neoadjuvant therapy shows promise in enhancing surgical success and survival in resectable and borderline resectable tumors. Postoperative complications such as pancreatic fistulas, delayed gastric emptying, and endocrine/exocrine insufficiencies are common challenges. For non-resectable tumors, palliative options such as biliary bypass and endoscopic stenting focus on symptom relief and quality of life. The surgical management of pancreatic masses has evolved significantly, driven by advancements in diagnostics, minimally invasive techniques, and supportive perioperative care. Emerging tools such as intraoperative imaging, artificial intelligence, and precision medicine are enabling more personalized treatment plans. A multidisciplinary approach remains critical in optimizing outcomes for patients with pancreatic neoplasms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.